Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Inc., and Medivation, Inc., a Pfizer Company.
International Ballroom South (Lobby Level)
720 S Michigan Avenue
Chicago, IL 60605
ASCO Bus Route 9 from McCormick Place
Despite the advances made in early detection, understanding of pathophysiology, and treatment and management of prostate cancer, many patients will require therapy beyond traditional androgen-deprivation therapy. The challenge in castration-resistant prostate cancer (CRPC) is its inherent heterogeneity with regard to clinical presentation and biomarkers, and that most tumors remain driven by androgen receptor signaling, which also impacts clinical decision making concerning treatment strategies. Patients with bone metastases represent an area in which multidisciplinary teams are essential to optimize outcomes.
Optimized treatment of CRPC is often best handled by a multidisciplinary team, including physicians (eg, oncologists, urologists, pathologists, radiologists, psychiatrists) and supportive staff (eg, nurse coordinators, social workers, physical therapists). In recent years, the treatment armamentarium for CRPC has expanded dramatically, providing more choices and greater potential to improve clinical outcomes, but also has increased the complexity of decision making. This is particularly the case with sequencing decisions that must be made between various approaches, which may differ with respect to their mechanisms of action, treatment-related toxicities, and clinical trial results. The lack of comparative data for many of these options also adds to the complexity at key decision points in care. The critical educational challenge in the field has been the translation of the latest evidence to the bedside so that strategies may be most optimally personalized and sequenced for patients with these most difficult-to-treat forms of prostate cancer.
This exciting, interactive, case-based Medical Crossfire® symposium will feature leading experts in prostate cancer management, and assist practitioners to practically apply personalized treatment strategies and sequencing of therapies in the care of their patients with CRPC.
This educational program is directed toward all attendees of the 2017 Annual Meeting in Chicago, including medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of CRPC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with CRPC will be invited to participate.
Upon completion of this activity, participants should be better able to:
Howard I. Scher, MD
D Wayne Calloway Chair in Urologic Oncology
Chief, Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018